CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...
Publications / Posters
Using Artificial Intelligence to Predict Response to Immunotherapy
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring more complex diagnostic algorithms that evaluate the role of PDL1 expression in tumor...
Pathology AI (Artificial Intelligence)
Key takeways: Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
Intelligent Pharma Partners: Pathology AI Needs a New Business Model
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for pathology AI lies in personalized medicine with big data. Better characterization of the patient...
2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc. (Flagship) with the 2018 Global Technology Innovation Award. Each year,...
Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual pathology. The study was published in the Archives of Pathology & Laboratory...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Recent Posts
NEWS
Recognizing women leaders in biotechnology
The COVID-19 pandemic has highlighted the important need for cutting-edge life science research and technology to improve health outcomes. The Healthcare Technology Report recently announced, “The Top 25 Women Leaders in Biotechnology of 2021”, which is comprised of...
Flagship Spotlight: Jordyn Vincelet – Sales Coordinator at Flagship Biosciences
Education and Early CareerJordyn received his Bachelor of Science in Community Health Sciences at the University of Nevada-Reno. Jordyn always wanted to be in the medical field, either in patient care or in medicine. According to an old yearbook, he actually wanted to...
Success Through Centralization? The Path to Realizing Digital Pathology’s True Value
The Pathologist, September, 2021: Success Through Centralization? The Path to Realizing Digital Pathology’s True ValueBy Flagship Biosciences Team Members: Geoffrey Metcalf, Meredith James, and Roberto GiananiDigital pathology’s benefits have been widely discussed –...
EVENTS
Spatial Biology for Drug Development Summit
Visit Flagship at the Spatial Biology for Drug Development Summit. October 11-13, 2023. Join us at the inaugural Spatial Biology for Drug Development Summit to explore implementation strategies, challenges in interpretation, and how this rapidly changing technology is...
13th Annual World Clinical Biomarkers & CDx Summit
Visit us at booth E30 to learn how we can partner for end-to-end support of your research and development program. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the 13th Annual World Clinical Biomarkers & CDx...
June 2023 Annual Meeting
Flagship Bioscience is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance your precision medicine strategy. Attending the 2023...